Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) will participate in the Piper Sandler 37th Annual Healthcare Conference, December 2–4, 2025. A fireside chat featuring Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO) is scheduled for Thursday, December 4, 2025 at 12:30 p.m. ET.

Interested parties can access a live webcast via the company’s Investor Relations Events & Presentation page. A replay will be archived on the Pliant website for 90 days after the event.

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37^th Annual Healthcare Conference to be held December 2 – 4, 2025.

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 4, 2025, at 12:30 p.m. Eastern Time.

Interested parties may access the live webcast of the fireside chat by visiting here or the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 90 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of α_vß₈ and α_vß₁ integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α₇β₁ targeting muscular dystrophies. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When will Pliant Therapeutics (PLRX) present at the Piper Sandler Healthcare Conference?

Pliant's fireside chat is scheduled for December 4, 2025 at 12:30 p.m. ET.

Who will represent Pliant Therapeutics (PLRX) at the December 2025 Piper Sandler conference?

Speakers are Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO).

How can investors watch Pliant Therapeutics' (PLRX) Piper Sandler fireside chat live?

Investors can view the live webcast via Pliant’s Investor Relations Events & Presentation page.

Will Pliant Therapeutics (PLRX) provide a replay of the Piper Sandler presentation?

Yes. The webcast replay will be archived on the Pliant website for 90 days after the event.

What topics will Pliant Therapeutics (PLRX) executives discuss at the December 4, 2025 fireside chat?

The company indicated executives will participate in a fireside chat covering recent developments and outlook; specific topics will be discussed during the session.

Where can I find the Pliant Therapeutics (PLRX) webcast after the Piper Sandler conference ends?

The replay will be available on Pliant’s Investor Relations Events & Presentation page for 90 days following the event.